A Verve Therapeutics treatment was found to cut cholesterol levels by more than half—with just one shot. The stock jumped ...

In a Phase Ib trial, VERVE-102 showed it could lower bad cholesterol across doses, setting up an opt-in decision for Eli ...

100 people who followed a low-carb keto diet were analyzed and high cholesterol was found to not be a marker for increased ...

A twice-a-day pill for the most common type of advanced breast cancer has been approved on the NHS in what scientists say is ...

AstraZenca is testing a once-daily PCSK9 inhibitor, currently known as AZD0780. After 12 weeks of use alongside standard ...

In a phase 2b study, treatment with a once-daily oral PCSK9 inhibitor added to statin therapy resulted in a more than 50% ...

New data from the PURSUIT Phase IIb trial reveal AstraZeneca‘s investigational oral PCSK9 inhibitor, AZD0780, delivers ...

On The Readout LOUD podcast, STAT reporters talk about new FDA commissioner Marty Makary's first week amid a swirl of layoffs ...

Discover March 2025’s top biotech deals, featuring major collaborations in small molecules, bispecific antibodies and protein ...

Positive results from the PURSUIT phase IIb trial for AstraZeneca’s AZD0780 demonstrated a statistically significant low-density lipoprotein cholesterol (LDL-C) reduction when administered on top of ...

Chronic stress can trigger changes in your body that can increase cholesterol levels. People at risk of heart disease from high cholesterol may benefit from stress management techniques.

AstraZeneca Plc’s experimental cholesterol drug significantly reduced “bad” cholesterol in a midstage trial, boosting hopes for a potential blockbuster that could be part of a powerful combination ...